Yazen closes oversubscribed €19.5 million series A round to accelerate growth and international expansion
Yazen Health, the leading healthcare platform dedicated to combating obesity with modern weight loss medication and lifestyle changes, announced today the successful closing of an oversubscribed €19.5 million Series A funding round. With this funding, the company strengthens its position as a pioneer in obesity treatment and sets its sights on international expansion. Mikael Hed, new chariman and Fredrik Meurling, CEO Yazen The funding round was co-led by Evli Growth Partners (Finland) and Helsana HealthInvest (Switzerland) with participation from Almaz Capital (Germany) and Yabeo